GEN Exclusives

More »

GEN News Highlights

More »
Jun 19, 2008

Kyowa Hakko Gains Asian Rights to Alnylam’s RSV Therapeutic in $93M Deal

  • Alnylam Pharmaceuticals and Kyowa Hakko Kogyo forged an exclusive alliance to develop and commercialize ALN-RSV01 in Japan and other major markets in Asia. ALN-RSV01 is Alnylam’s lead RNAi therapeutic, which is in Phase II development for the treatment of respiratory syncytial virus infection.

    Kyowa Hakko will pay Alnylam $15 million upfront and up to an additional $78 million in development and sales milestone payments. Upon commercialization, Alnylam will receive double-digit royalties from Kyowa Hakko based on the sales of ALN-RSV01 in this territory. The partnership also includes additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program. Alnylam retains all development and commercialization rights worldwide, excluding Asia.

    Related Links:

    RNAi Researchers Galvanized by Advances

    RNAi Technologies Become Discovery Staple

    Multidisciplinary Approach to RNAi



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?